Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dobutamine starting-dose trial for neonatal haemodynamic insufficiency
2017-002875-25Phase 3Active
- Sponsor
- FIBHULP
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dobutamine in Neonatal hypoperfusion and Cardiovascular collapse (3 arms), sponsored by FIBHULP. Primary endpoints: Co-primary efficacy endpoints and Short-term haemodynamic response. Started Jan 2018; status: active.
02
Drugs
dobutamine
03
Conditions
Neonatal hypoperfusionCardiovascular collapse
Beyond the preview
Go deeper on 2017-002875-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002875-25.